These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8595995

  • 1. Maintenance strategies in Crohn's disease.
    Sachar DB.
    Hosp Pract (1995); 1996 Jan 15; 31(1):99-106. PubMed ID: 8595995
    [Abstract] [Full Text] [Related]

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH, Munck LK.
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar 15; 4(3):160-70. PubMed ID: 17339853
    [Abstract] [Full Text] [Related]

  • 3. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC, Hanauer SB.
    Rev Gastroenterol Disord; 2004 Mar 15; 4(3):104-17. PubMed ID: 15359211
    [Abstract] [Full Text] [Related]

  • 4. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM.
    Dan Med Bull; 2011 Dec 15; 58(12):B4360. PubMed ID: 22142578
    [Abstract] [Full Text] [Related]

  • 5. Medical treatment of inflammatory bowel disease: new therapies, new drugs.
    Sutherland LR.
    CMAJ; 1987 Nov 01; 137(9):799-802. PubMed ID: 2894889
    [Abstract] [Full Text] [Related]

  • 6. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
    Maier K, Fischer C, Klotz U, Heinkel K.
    Dtsch Med Wochenschr; 1982 Jul 23; 107(29-30):1131-4. PubMed ID: 6123426
    [Abstract] [Full Text] [Related]

  • 7. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE, Helmstädter V.
    Dtsch Med Wochenschr; 1986 May 02; 111(18):721-2. PubMed ID: 2870908
    [No Abstract] [Full Text] [Related]

  • 8. [Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches].
    Cigala O, Pancallo MT, Marasco A, Della Valle M.
    Clin Ter; 1990 Jul 31; 134(2):101-10. PubMed ID: 1979263
    [Abstract] [Full Text] [Related]

  • 9. [Ulcerative colitis and Crohn disease. Early diagnosis and therapy].
    Wienbeck M, Purrmann J, Miller B.
    Internist (Berl); 1986 Mar 31; 27(3):166-71. PubMed ID: 2872183
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Inflammatory bowel diseases].
    Kruis W.
    Dtsch Med Wochenschr; 2004 Sep 03; 129 Suppl 2():S73-5. PubMed ID: 15368174
    [No Abstract] [Full Text] [Related]

  • 13. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR, Mays DA.
    Ann Pharmacother; 1997 Sep 03; 31(7-8):907-13. PubMed ID: 9220055
    [Abstract] [Full Text] [Related]

  • 14. Clinical aspects of ulcerative colitis in mainland China.
    Zheng JJ.
    Chin J Dig Dis; 2006 Sep 03; 7(2):71-5. PubMed ID: 16643333
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
    Segars LW, Gales BJ.
    Clin Pharm; 1992 Jun 03; 11(6):514-28. PubMed ID: 1600685
    [Abstract] [Full Text] [Related]

  • 17. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ.
    Rev Gastroenterol Disord; 2006 Jun 03; 6(2):97-105. PubMed ID: 16699478
    [Abstract] [Full Text] [Related]

  • 18. Medical management of patients with difficult-to-treat inflammatory bowel disease.
    van Hogezand RA.
    Neth J Med; 1994 Aug 03; 45(2):55-9. PubMed ID: 7936006
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.